乳腺癌患者血清瘦素、可溶性瘦素受体及雌二醇测定的意义  

Clinical significance of serum leptin,soluble leptin receptor and estradiol in breast cancer patients

作　　者：孙钧铭[1] 姜东林[1] 薛敏[1] 胡绍碧[1] 

机构地区：[1]无锡市第三人民医院中心实验室,214041

出　　处：《中华核医学杂志》2006年第6期360-362,共3页Chinese Journal of Nuclear Medicine

摘　　要：目的探讨测定乳腺癌患者血清瘦素(Lp)、可溶性瘦素受体(sLR)及雌二醇(E_2)水平的临床意义。方法分别用放射免疫分析法、化学发光免疫法、ELISA法测定55例乳腺癌患者血清Lp、E_2和sLR水平,并同步测量体重指数(BMI),与20例良性乳腺疾病和20例健康体格检查者相应指标进行比较。结果乳腺癌组血清Lp、BMI和E_2水平明显高于健康对照组(P分别＜0．01、＜0．05), sLR水平与健康对照组相比呈下降趋势(P＜0．05)。Lp对乳腺癌的诊断灵敏度为47．27%(26/55例)、特异性为92．50%(37/40例);E_2对乳腺癌的诊断灵敏度为43．64%(24/55例)、特异性为97．50%(39/40例),而2项联合检查对乳腺癌的诊断灵敏度为69．09%(38/55例)、特异性为92．50%(37/40例)。结论乳腺癌患者Lp和E_2呈过表达现象。测定血清Lp、sLR及E_2水平对研究乳腺癌的发生、发展及其诊断和探讨其与肥胖的关系都具有重要意义。Objective To evaluate the clinical significance of serum leptin （Lp）, soluble leptin receptor（sLR） and estradiol （E2 ） in breast cancer patients. Methods Ninety-five subjects were enrolled. Twenty were healthy volunteers, 20 were patients with benign breast diseases and 55 were documented breast cancer patients. All had serum-Lp （radioimmunoassay） , sLR （ELISA） , body mass index （ BMI ） and E2 （chemical luminescence immunoassay） evaluation. Results Significantly higher Lp （P 〈 0.01 ）, BMI （ P 〈 0.05 ） and E2 （ P 〈 0.01 ） and lower sLR （ P 〈 0.05 ） were observed in cancer patients than in normal volunteers. The sensitivity and specificity of Lp, E2 alone and combination in detecting breast cancer were 47.27% and 92.50% （ Lp）, 43.64% and 97.50% （ E2 ） , 69.09% and 92.50% （combination） respectively. Conclusion Both Lp and E2 are potential indicators to monitor tumor growth in breast cancer patients.

关 键 词：乳腺肿瘤 瘦素 受体 瘦素 雌二醇 免疫测定 

分 类 号：R737.9[医药卫生—肿瘤]